SCHEMBL140063

SCHEMBL140063

CCCCCCCCCCCC=CC=CC=CC=CC=C(O)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FASN P49327 1/20 0.61
ALDH1A1 P00352 1/20 0.53
TSHR P16473 1/20 0.53
FAAH O00519 3/20 0.51
KDM4E B2RXH2 1/20 0.51
TERT O14746 3/20 0.50
PTPN1 P18031 3/20 0.50
PPARG P37231 3/20 0.50
PPARD Q03181 3/20 0.50
PPARA Q07869 3/20 0.50
MAPT P10636 2/20 0.50
BLM P54132 2/20 0.50
HSD17B10 Q99714 2/20 0.50
FABP4 P15090 2/20 0.50
GMNN O75496 1/20 0.50
USP2 O75604 1/20 0.50
LMNA P02545 1/20 0.50
CYP1A2 P05177 1/20 0.50
POLB P06746 1/20 0.50
CYP2C9 P11712 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30000546 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL1427212 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL29253334 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL1427215 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL1055870 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL1039992 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL140696 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL2732862 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL15048699 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E
SCHEMBL28614760 1.00 FASN (0.61) FASNALDH1A1TSHRFAAHKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3892608-B1 NOVEL N-3 IMMUNORESOLVENTS: STRUCTURES AND ACTIONS BRIGHAM & WOMENS HOSPITAL INC (US) 2025-07-23 EP disclosed
EP-4031871-B1 METHODS FOR PREDICTING PATIENT RESPONSE TO DMARDS UNIV LONDON QUEEN MARY (GB) 2024-07-24 EP disclosed
CN-114075388-B Thermosetting release coating agent, cured product, thermosetting release film, and method for producing same 荒川化学工业株式会社 2023-10-20 CN disclosed
CN-116693932-A Regenerated polymer material and method for producing same, cleaning agent and method for producing regenerated polymer 荒川化学工业株式会社 2023-09-05 CN disclosed
US-11667598-B2 N-3 immunoresolvents: structures and actions THE BRIGHAM & WOMEN'S HOSPITAL INC. (US) 2023-06-06 US disclosed
US-11555006-B2 Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2023-01-17 US disclosed
US-20220349886-A1 Methods for Predicting Patient Response to DMARDs QUEEN MARY UNIVERSITY OF LONDON (GB) 2022-11-03 US disclosed
EP-4031871-A1 METHODS FOR PREDICTING PATIENT RESPONSE TO DMARDS Queen Mary University of London (GB) 2022-07-27 EP disclosed
CN-114075388-A Thermosetting release coating agent, cured product, thermosetting release film, and method for producing same 荒川化学工业株式会社 2022-02-22 CN disclosed
EP-3892608-A1 NOVEL N-3 IMMUNORESOLVENTS: STRUCTURES AND ACTIONS The Brigham and Women's Hospital, Inc. (US) 2021-10-13 EP disclosed
EP-3103787-A1 METHOD FOR CHEMICAL CONVERSION OF UNSATURATED FATTY ACID BY CARBON CHAIN EXTENSION REACTION Bizen Chemical Co., Ltd. (JP) 2016-12-14 EP disclosed
US-20160115112-A1 NOVEL N-3 IMMUNORESOLVENTS: STRUCTURES AND ACTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-04-28 US disclosed
EP-3003299-A2 NOVEL N-3 IMMUNORESOLVENTS: STRUCTURES AND ACTIONS The Brigham And Women's Hospital Inc. (US) 2016-04-13 EP disclosed
US-9238634-B2 Anti-inflammatory metabolite derived from omega-3-type fatty acid THE UNIVERSITY OF TOKYO (JP) 2016-01-19 US disclosed
WO-2014193652-A2 NOVEL N-3 IMMUNORESOLVENTS: STRUCTURES AND ACTIONS THE BRIGHAM & WOMEN'S HOSPITAL INC. (US) 2014-12-04 WO disclosed
US-8853437-B2 Anti-inflammatory compounds THE UNIVERSITY OF TOKYO (JP) 2014-10-07 US disclosed
US-20130274327-A1 NOVEL ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3-TYPE FATTY ACID THE UNIVERSITY OF TOKYO (JP) 2013-10-17 US disclosed
EP-2607358-A1 NOVEL ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3-TYPE FATTY ACID The University of Tokyo (JP) 2013-06-26 EP disclosed
US-20120059061-A1 NOVEL ANTI-INFLAMMATORY COMPOUNDS THE UNIVERSITY OF TOKYO (JP) 2012-03-08 US disclosed
EP-2415748-A1 NOVEL ANTI-INFLAMMATORY COMPOUNDS The University of Tokyo (JP) 2012-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059061-A1 NOVEL ANTI-INFLAMMATORY COMPOUNDS ALOX15, ALOX15B, ALOX12 FASN 66/4885ALDH1A1 1074/4885TSHR 4542/4885
US-11555006-B2 Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections ALOX12, ALOX15, FPR2 FASN 19/4885ALDH1A1 3891/4885TSHR 4356/4885
US-20160115112-A1 NOVEL N-3 IMMUNORESOLVENTS: STRUCTURES AND ACTIONS ALOX15B, ALOX15, ALOX12 FASN 14/4885ALDH1A1 1680/4885TSHR 3291/4885
US-20130274327-A1 NOVEL ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3-TYPE FATTY ACID PTGES3, ALOX5, ALOX15 FASN 15/4885ALDH1A1 895/4885TSHR 4531/4885
US-11667598-B2 N-3 immunoresolvents: structures and actions HPGDS, ALOX5, ALOX15B FASN 14/4885ALDH1A1 760/4885TSHR 2521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.